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Abstract 
Aptamers are novel oligonucleotides with flexible three-dimensional configurations that recognize 
and bind to their cognate targets, including tumor surface receptors, in a high-affinity and highly 
specific manner. Because of their unique intrinsic properties, a variety of aptamer-mediated 
nanovehicles have been developed to directionally transport anti-cancer drugs to tumor sites to 
minimize systemic cytotoxicity and to enhance permeation by these tumoricidal agents. Despite 
advances in the selection and synthesis of aptamers and in the conjugation and self-assembly of 
nanotechnologies, current chemotherapy and drug delivery systems face great challenges. These 
challenges are due to the limitations of aptamers and vehicles and because of complicated tumor 
mechanisms, including heterogeneity, anti-cancer drug resistance, and hypoxia-induced aber-
rances. In this review, we will summarize current approaches utilizing tumor surface hallmarks and 
aptamers and their roles and mechanisms in therapeutic nanovehicles targeting tumors. Delivery 
forms include nanoparticles, nanotubes, nanogels, aptamer-drug conjugates, and novel molecular 
trains. Moreover, the obstacles posed by the aforementioned issues will be highlighted, and pos-
sible solutions will be acknowledged. Furthermore, future perspectives will be presented, including 
cutting-edge integration with RNA interference nanotechnology and personalized chemotherapy, 
which will facilitate innovative approaches to aptamer-based therapeutics. 
Key words: aptamer, biomarker, chemotherapy, drug delivery, nanomedicine. 
Introduction 
Cancer is the top public health problem all over 
the world. It was reported to be the second major 
cause of mortality in the U.S. in 2013, with 1.66 million 
new cases and 0.58 million deaths [1]. Moreover, it is 
estimated that developing countries contribute 56% of 
new cases and 64% of deaths to the worldwide total 
[2].  In China, annual statistics showed 3.09 million 
new cases and 1.96 million deaths [3]. Skyrocketing 
investment have been devoted to the battle against 
cancer (with an economic cost of over $1.2 trillion in 
the U.S. in 2013 [4]), which has become one of the top 
priorities for biotechnological research and pharma-
ceutical innovation worldwide.  
 At present, the most commonly adopted an-
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ti-cancer treatments are chemotherapeutics. Although 
current chemotherapy regimens present modest sur-
vival benefits, they still encounter drastic limitations 
in terms of associated poor tissue selectivity, rapid 
systemic clearance, low intratumoral  accumulation 
and drug resistance. Thus, many patients succumb to 
the adverse effects of myelosuppression and cardio-
toxicity far earlier than elevation of the tumor burden 
[5]. Therefore, the accurate delivery of chemothera-
peutic drugs to tumor sites while sparing normal tis-
sue is of utmost importance. Current approaches in 
nanotechnology have inspired most aspects of deliv-
ery vehicles, such as optimized encapsulation, im-
proved targeting, and controlled release, among oth-
ers [6, 7]. In many cases, nanoparticles (NPs) have 
shown great potential for targeted drug delivery due 
to their enhanced permeability and retention (EPR) 
effect [8]. Regarding directional agents, antibodies 
were previously the primary tools, but novel targeting 
agents, including aptamers, short peptides, and other 
small molecules, have recently become the new gen-
eration of targeting molecules [9-11]. 
Correspondingly, one of the most promising 
drug delivery strategies is aptamer-mediated nano-
vehicles  (AMNVs). Aptamers are newly emerging 
small nucleic-acid ligands that target various disease 
markers, and they also represent an interesting class 
of novel pharmaceuticals due to their advantageous 
properties for research, diagnostics and therapeutics 
[12]. One milestone achieved in the translation of ap-
tamer nanotechnology is the development of 
Macugen (also known as pegaptanib; Fig. 1A), which 
is used for the treatment of human macular degener-
ation. More specifically, Macugen is an RNA aptamer 
that antagonizes the binding of vascular endothelial 
growth factor (VEGF) to its receptor [13]. This pio-
neering attempt greatly inspired the exploration of 
AMNVs for cancer therapy. Additionally, a variety of 
aptamers targeting different cancer markers are cur-
rently under preclinical and clinical investigation. Our 
recent search for “aptamer AND drug delivery” re-
turned over 2480 publications, which accounted for 
5% of all results obtained when searching for “tar-
geted drug delivery AND cancer/tumor” in the Med-
line database. This review aims to summarize the 
evolution of aptamers and their tumor counterparts, 
the current applications of AMNVs in major tumor 
models and their associated limitations, as well as the 
therapeutic implications for nanomedicine. In partic-
ular, we discuss the inspirations for the development 
of AMNVs and future perspectives from the point of 
view of recently emerging tumor concepts, including 
tumor heterogeneity, multiple drug resistance (MDR) 
and personalized nanomedicine. 
 
 
Figure 1. A conformational and interactional overview of aptamers and their receptors. (A) The sequential conformation (left) and secondary 
structure (right) of the commercialized aptamer product Macugen. (B) Schematic illustrations (left) and molecular models (right) of the quadruplex DNA 
for the aptamer AS1411. (C) The overall structure of the RNA aptamer C13 and its receptor, G protein-coupled receptor kinase 2 (GRK2). C13 positions 
an adenine nucleotide in the ATP-binding pocket of GRK2 (shown as yellow and burgundy ribbons), which stabilizes GRK2 in a unique and remodeled 
conformation. The terminal stem of the aptamer indirectly contributes to its affinity. Adapted from [18, 29].  Theranostics 2014, Vol. 4, Issue 9 
 
http://www.thno.org 
933 
General profile of aptamers and relevant 
significance 
 In contrast to linear  oligonucleotides, such as 
micro-RNAs (miRNAs) and small interfering RNAs 
(siRNAs), which contain genetic sequences or anti-
sense oligonucleotides that interrupt gene transcrip-
tion, aptamers are short (20-80 bp), single-stranded, 
and well-formed 3D-configured RNA or DNA ligands 
(Fig. 1A). Aptamers bind with high affinity and spec-
ificity to their target molecules, which include pro-
teins, phospholipids, iron channels, nucleic acids, and 
whole cells, among others [14]. These oligonucleotides 
are also called “smart ligands” due to their superior 
advantages in terms of small size, flexible structure, 
and selective internalization and intratumoral pene-
tration. Aptamers are also easy to inexpensively syn-
thesize, show low antigenic and immunogenic poten-
tial, and enable chemical modifications for various 
applications [15]. Aptamers are typically isolated and 
synthesized from large randomized oligonucleotide 
libraries by a process known as in vitro systematic 
evolution of ligands by exponential enrichment 
(SELEX), which is a combinatorial biochemical tech-
nique for producing oligonucleotides that specifically 
bind to a particular ligand via multiple rounds of se-
lection [16].  
 Given exonuclease degradation, various meth-
ods have been adopted to synthesize aptamers with 
enhanced stability, such as by replacing the phosphate 
in the backbone with phosphorothionate or by deri-
vatizing the 2’-ribose in pyrimidines and the 
3’-inverted deoxythymidine cap [17]. Moreover, ap-
tamers can be readily modified by adding poly (eth-
ylene glycol) (PEG) and other moieties to reinforce the 
oligonucleotides’ bioavailability and pharmacokinetic 
properties. 
 Interaction of aptamers with tumors 
 Because  of their unique properties, aptamers 
have emerged as novel and promising molecules that 
target specific cancer epitopes for clinical diagnosis 
and therapy, comparable to antibodies. Aptamers’ 
role in directionally guiding drugs to specific tumor 
lesions is achieved by working as a molecular probe to 
recognize and bind to corresponding receptors. In 
contrast to antigen-antibody interactions, an aptamer 
remodels its three-dimensional structure spontane-
ously and caters to the individual configuration of a 
receptor [18] (Fig. 1B, C). Human tumors show in-
trinsic pathological characteristics, and aptamers are 
sensitive in identifying these tumor-specific signa-
tures, with the goal of improving diagnostic and 
therapeutic responses and reducing unnecessary tox-
icity in oncology patients. In this respect, a major 
challenge is the identification of specific cell signa-
tures among low-content molecular targets in the 
presence of abundant, nonspecific plasma-membrane 
antigens. Here, we summarize most of the currently 
known biomarkers expressed on tumor cell surfaces 
that potentially interact with the aptamers in Table 1. 
 
Table 1. Verified hallmarks on tumor cell surface for potential tumoricidal targeting 
Biomarker   Classification  Known expressing tumors  Role in Tumorigenesis  Reference 
Prostate specific mem- 
brane antigen (PSMA) 
Type II transmembrane 
proteins 
Prostate, kidney , bladder cancers, etc.  Catalyzing the hydrolysis of N-acetylaspartyl- 
glutamate for cancer cell over-proliferation. 
Benjamin T, et al.2013. 
V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene 
homolog (KRAS) 
Ras family member and 
GTPase proteins 
Pancreatic, colorectal, lung cancers, mucin-
ous adenoma, ductal carcinoma, leukemia, 
etc. 
Product of Kirsten ras proto-oncogene 
switching the propagating of growth factors 
and receptor’s signal (c-Raf, PI3KCG, 
RALGDS, RASSF2). 
Miles KA, et al. 2014. 
RET receptor tyrosine 
kinase (RTK) 
Flial cell-derived neu-
rotrophic factor family 
members 
Thyroid, breast, lung cancers, etc.  RET proto-oncogene signaling by oncogenic 
mutation, gene rearrangement, overexpres-
sion or transcriptional up-regulation. 
Plaza-Menachol I, et al. 
2014. 
Human epidermal 
growth factor 2 (HER2) 
Membrane tyrosine 
kinases 
Breast, gastric, lung, bladder, colorectal, 
esophageal, ovarian cancers, etc. 
Tumorigenic signaling via MAPK, PI3K/Akt, 
PKC and STAT pathways. 
Krishnamurti U, et al. 
2014. 
Epithelial cell adhesion 
molecule (EpCAM) 
Type I transmembrane 
glycoproteins 
Bladder, breast, colon, esophagus, lung, 
hepatocellular, ovarian, pancreas, prostate, 
etc. 
Regulating gene expression of c-myc, e-fabp, 
cyclin, etc. and modulating EMT. 
Patriarca C, 2012. 
Nestin  Class VI intermediate 
filament family members 
Prostate, breast, pancreatic, ovarian, cervical 
cancers, glioblastoma, lung adeonocarcino-
ma, multiple myeloma, etc. 
Influencing FAK and integrin localization and 
modulating Akt/Sox-2 for tumor invasion. 
Hyder CL et al. 2014; 
Chen ZG, et al. 2014; 
Narita K, et al. 2014. 
Annexin A2 (p36)  Calcium dependent 
phospholipid-binding 
proteins 
Leukemia, breast, gastric, lung, pancreatic 
cancers, hepatocellular, colorectal, squa-
mous cell carcinomas, multiple myeloma, 
etc. 
Regulating tumor behaviors such as neoan-
giogenesis, migration and invasion, and 
chemoresistance 
Cibiel A, et al. 2014; 
Wang CY, et al. 2014. 
Tumor endothelial 
marker 1 (TEM 1) 
C-type lectin trans- 
membrane receptors 
Most sarcomas, brain tumors, etc.  Promoting angiogenesis via HIF-2α pathway   Facciponte JG, et al. 2014; 
Bagley RG. 2009. 
Mucin 1 (MUC1)  Members of the mucin 
family 
Ovarian, breast, lung, pancreatic cancers, 
pros- tate adenocarcinoma, multiple mye-
loma, etc. 
Promoting cancer cell invasion through 
beta-catenin and initiating EMT. 
Dalziel M, et al.1999. 
Nucleolin (NCL)  Multi-functional proteins 
translocated from nucleic 
Gastric, lung, colorectal, prostate, breast 
cancers, melanomas, glioblastoma, gliomas, 
osteosarcoma , leukemia, etc. 
Activating CXCR4 signaling to promote EMT, 
inhibiting Fas-mediated apoptosis and IL-9 
dependent apoptosis. 
Yang X, et al. 2014; 
Wise JF, et al. 2013; 
Shang Y, et al. 2012.  Theranostics 2014, Vol. 4, Issue 9 
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Endoglin (CD105)  Type III TGF-β super- 
family receptors 
Renal cell, hepatocellular carcinoma, gastric, 
prostate cancers , sarcoma, leukemia, etc. 
Development of resistance VEGF inhibition;  
Modulating tumor growth and metastasis via 
TGF-B receptor signaling. 
Rosen LS, et al. 2014; 
Breen MJ, et al. 2013. 
CD24, 30, 44, 133, 166.  Surface transmembrane 
glycoproteins 
Breast, brain, colon, gastric, lung, prostate 
cancers, leukemia, Hodgkin’s lymphoma, et 
al. 
Regulating tumor cell prolifera-
tion, differentiation, migration, angiogenesis. 
Schmitt F, et al. 2014, 
Ni C, et al. 2013; 
Wen L, et al. 2013;  
Takaishi K, et al. 2009. 
Integrin α3βv, α2β1, α5β1  Cell surface adhesion 
molecules 
Breast, pancreatic, leukemia, prostate, colo-
rectal cancers, sarcoma, etc. 
Promoting tumorigenesis by transducting 
stimuli from ECM to oncogenic signal trans-
ducers of ErbB, Ras, and Src, etc. 
Chen JC, et al. 2013. 
CXCR4  Chemokine (C-X-C 
motif) receptors 
Gliomas, renal cell carcinoma, lymphoma, 
bre- ast, leukemia, gastric, ovarian, colorec-
tal, etc. 
Modulating tumor proliferation, invasion, 
angiogenesis and immune response. 
Gagliardi F, et al.2014. 
CXCR3  Chemokine (C-X-C 
motif) receptors 
Breast, gastric, cancers, melanoma, renal cell 
carcinoma, etc. 
Inducing cell growth, mobility and invasion 
and angiogenesis. 
Billottet C, et al.2013. 
Vascular endothelial 
growth factor receptor 
(VEGF-R) 
Type V receptor tyrosine 
kinases 
Ovarian, breast, cervical, lung cancers, 
thyroid, renal cell carcinoma, etc. 
Key regulator in tumor angiogenesis and 
angiogenesis. 
Shibuya M, et al.2014; 
Stuttfeld E, et al.2009. 
Platelet derived growth 
factor receptor (PDGF-R) 
Cell surface tyrosine 
kinase receptors 
Gastrointestinal stromal tumors, leukemia, 
multiple myeloma, dermatofibrosarcoma, 
melanoma, glioblastoma, etc. 
Modulating epithelial-mesenchymal transi-
tion (EMT) and tumor addiction by 
over-expression or mutation. 
Heldin CH, et al.2013. 
Hepatocyte growth factor 
receptor (HGFR/MET) 
Transmembrane receptor 
tyrosine kinases 
Colorectal, lung, breast, pancreatic, ovarian, 
gastric, endometrial cancers, etc. 
Product of c-Met proto-oncogene modulating 
oncogenic pathways (RAS, PI3K, STAT3, 
beta-catenin) and angiogenesis. 
Peng Z, et al. 2014; 
Harshman LC, et al. 2013; 
Mahlknecht G,2013 
Ephrin type-B receptor 4 
(EphB4) 
Eph receptor tyrosine 
kinases 
Breast, , prostate, lung cancers, mesothelio-
ma, glioblastoma, etc. 
Regulating tissue homeostasis including 
tissue boundaries formation, intricate neu-
ronal circuits assembly, blood vessels remod-
eling. 
Pasquale EB. 2010. 
IL-6 receptor (CD126)  Type I cytokine  
receptors 
Colon, ovarian and pancreatic cancers, mul- 
tiple myeloma, hepatocellular carcinoma, 
etc. 
Promoting EMT via IL-6R/STAT3, GP130, 
Cyclin D1, Bcl-xl, etc. 
Rokavec M, et al.2014; 
Cui X, et al. 2014 
Transforming growth 
factor β receptor (TGF-β 
R) 
Single pass serine/ 
threonine ki-
nase receptors 
Breast, lung, colon, prostate, pancreatic 
cancers, ductal adenocarcinoma, hepatocel-
lular carcinoma, etc. 
Promoting EMT via interaction with autocrine 
or paracrine growth factors and inducting 
microenvironment. 
Giannelli G, et al. 2014; 
Hiemer SE, et al. 2014. 
Transcobalamin II re-
ceptor (TCII-R) 
Plasma membrane 
receptors 
Breast, pancreatic, ovarian, lung cancers , 
renal adenocarcinoma, Ewing’s sarcoma, 
glioblasto- ma, leukemia, Burkitt’s lym-
phoma, etc. 
Vitamin B12-dependent cellular replication 
for tumor proliferation. 
Sysel AM, et al. 2013; 
Amagasaki T, et al. 1999; 
Seetharam B, et al. 1999. 
Protein tyrosine kinase 7 
(PTK7) 
Tyrosine kinase-like 
transmembrane recep-
tors  
T-cell acute lymphoblastic leukemia, lung, 
gastric cancers, colon carcinoma, etc. 
Regulating planar cell polarity, cell migration 
and invasion via non-canonical Wnt signal-
ing. 
Shangguan D, et al. 2008; 
Peradziryi H, et al. 2011 
Na HW, et al. 2012 
 
 
 
Delivery formulations of AMNVs to tumors 
 The current paradigm of an aptamer-mediated 
tumoricidal therapeutic approach is to develop du-
al-functional complexes consisting of an outstanding 
aptamer guide that targets the extracellular region of a 
tumor-specific surface biomarker and a cargo portion 
that carries a cytotoxic agent. To date, the most com-
monly employed vehicles are aptamer-linked NPs 
encapsulating a hydrophobic chemotherapeutic agent 
(NPs; Fig. 2A). These NPs show great diversity based 
on their drug-loading characteristics, and they may be 
classified primarily as polymeric NPs (e.g., poly (lac-
tide-co-glycolide), or PLGA), metallic NPs (e.g., gold 
NPs, or GNPs), magnetic NPs (e.g., Fe3O4), silica NPs, 
liposomes, micelles, and quantum dots (QDs), among 
others [19-22]. These vehicles are advantageous for 
drug loading and an extended period of chemother-
apeutic drug administration because the drug cargo is 
independent. Most studies have shown over 5% 
loading capability, an encapsulation efficacy of up to 
90%, and in vitro release profiles over 48 hours (Table 
2).  
 
Another derivation from nanoscaled drug de-
livery system, termed as “aptamer-drug conjugate,” 
has been generated to overcome the complicated as-
sembly techniques and low controllability of 
site-specific drug conjugation [23]. The simple assem-
bly largely relies on the structural property of the 
drug and its noncovalent association with specific 
DNA sequences. One classical example is the  an-
thracycline class of anti-cancer drugs, such as doxo-
rubicin (Dox), which prefer to bind to a repetitive se-
quence (5’-CG-3’) in aptamers and to intercalate 
within the GC pairs to form physical conjugates at 
certain molar ratios [24]. Under these circumstances, 
the aptamer acts both as a guide and as a cargo for 
drug delivery (Fig. 2B and C). The superiority of these 
agents is achieved via their improved binding affinity 
(Kd=1-10 nM), their ability to be efficiently internal-
ized by many cancer cells, and their ability to pass 
through the blood-brain/blood-tumor barriers [25]. 
However, the majority of these approaches have suf-
fered from low synthesis yield, reduced drug loading 
capacity and rapid elimination by systemic clearance.  Theranostics 2014, Vol. 4, Issue 9 
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Table 2. Publications of aptamer-mediated nano-vehicles, physico-chemical and tumoricidal characterizations in the recent years. 
Aptamer 
/Target 
Type 
(bp) 
Physico-chemical Property  Anti-tumor Potency  Reference 
Vehicle  Drug  Drug loading  Release profile  Cancer model(cell line)  Study type 
AS1411 
/NCL 
DNA (28)  Triblock co- polymer 
NPs* 
Dox  LP 3.64%   pH-responsive:  
70.30% in PBS, 48h 
MCF-7, PANC-1  In vitro  Lale SV, et al. 
2014 
DNA (28)  Carbon nanotube  Dox  DNS  DNS  Nude mice bearing xeno-
graft (PC3 cell) 
In vitro & 
In vivo 
Zhang H, et al. 
2014 
DNA (38)  Liposome  Dox  LP 12.5%   Hydrolytic release:  
10% in plasma, 24h 
Nude mice bearing xeno-
graft (MCF-7) 
In vitro & 
In vivo 
Xing H, et al. 
2013 
DNA (26)  Mesoporous silica 
NPs 
Dox  LP 4.6%   pH-responsive:  
72% in PBS, 50h 
MCF-7,MDA MB-231  In vitro  Li LL, et al. 
2012 
DNA (26)  PLGA-lecithin-PEG 
NPs 
Ptx  EE 60.93%  Hydrolytic release:  
94% in PBS, 120h 
GI-1, MCF-7  In vitro  Aravind A, et 
al. 2012 
DNA (28)  PEG-PLGA NPs  Ptx  EE 44.7%,  
LP 1.02%  
Hydrolytic release: 78.4% in 
PBS, 84.1% in plasma, 12d 
Nude mice bearing xeno-
graft (C6 glima cell) 
In vitro & 
In vivo 
Guo JW, et al. 
2011 
DNA (26)  Silica-coated gold 
nanorods 
Dox  LP 3.8%  photothermo-responsive 
release 
MCF-7  In vitro  Yang XJ, et al. 
2012 
A10 
/PSMA 
RNA (57)  Unimolecular mi-
celles NPs 
Dox  LP 10.4%  pH-responsive:  
91% in PBS, 45h 
Nude mice bearing xeno-
graft (CWR22Rv1 cells) 
In vitro & 
In vivo 
Xu WJ, et al. 
2013 
RNA (57)  PLA-PLGA NPs  Platinum 
Docetaxel 
Pt: EE95%, LP 5%;  
Dtx: EE80%, LP 1%. 
Hydrolytic release: 98% 
Dxtl and 80%, Pt in PBS, 
72h 
LNCaP  In vitro  Kolishetti N, et 
al. 2010 
RNA (57)  PLGA NPs  Platinum  LP 5%  DNS  Nude mice bearing xeno-
graft (LNCaP) 
In vivo  Dhar S, et al. 
2010 
RNA (91)  Golden-NPs  Dox  Apt-Dox ratio: 2:15 
(molar) 
Hydrolytic release:  
52% in PBS, 24h 
LNCaP  In vitro  Kim, D, et al. 
2010 
RNA (57)  QD-Apt-drug con-
jugate 
Dox  QD−Apt/Dox ratio: 
1/7 (molar) 
DNS  LNCaP  In vitro  Bagalkot V et 
al. 2009 
SZTI01 
/PSMA 
DNA (48)  Dimeric apt- drug 
complex 
Dox  Apt-Dox ratio: 1:4 
(molar) 
Hydrolytic release:  
40% in PBS, 6h 
C4-2 cells  In vitro  Boyacioglu O, 
et al. 2013 
5TR1 
/MUC1 
DNA (25)  Apt-SPION complex  Epirubicin  LP 2.27%  DNS  BALB/c mice bearing 
xenograft (C26 cells) 
In vitro &  
in vivo  
Jalalian SH, et 
al. 2013 
MA3 
/MUC1 
DNA (86)  Apt-drug conjugate  Dox  Apt-dox ratio: 1/10 
(molar) 
DNS  A549 lung cancer, MCF-7   In vitro  Hu Y, et al. 
2012 
Apt 
/MUC1 
DNA (25)  DNA Icosahedral  Dox  LP 40%  DNS  CHO-K1, MCF-7   In vitro  Chang M, et al. 
2011 
S2.2 
/MUC1 
DNA (19)  PLGA NPs  Ptx  EE 83.6%, LP 4.2%  Hydrolytic release:  
65% in PBS, 48h 
MCF-7,HepG2  In vitro  Yu CC , et al. 
2011 
Apt 
/MUC1 
DNA (25)  QD-Apt-Dox conju-
gate 
Dox  QD-dox ratio: 1/46 
(molar) 
pH-responsive:  
35%, 5h 
athymic nu/nu mice bear-
ing xenograft (A2780/AD 
cells) 
In vitro &  
in vivo 
Savla R, et al. 
2011 
Sgc8c 
/PTK7 
DNA (41)  PLGA hybrid NPs  Ptx, 
Dox 
LP 3.5%, EE35%.  DNS  CEM cells and Ramos cells  In vitro  Huang FJ, et al. 
2014 
DNA (41)  Apt-drug conjugate  Fluoroura-
cil 
Apt/drug ratio: 1/5 
(molar) 
Photo-controllable release  HCT116 cells  In vitro  Wang RW, et 
al. 2014 
DNA (41)  Apt -drug Nanotrain  Dox  Apt-NTr/drug ratio: 
1/50 (molar) 
DNS  NOD. Cg-Prkdc mice bear- 
ing xenograft (CCRF-CEM) 
In vitro & 
in vivo 
Zhu GZ, et al. 
2013 
DNA (41)  AuNR-based Nano-
gel 
Dox  DNS  Photothermo-responsive: 
74%, 50min 
CCRF-CEM cells, Ramos 
cells 
In vitro  Kang HZ, et al. 
2011 
DNA (41)  Lipid-coated droplet  Dox  EE 50.6%, LP 30.4%  Ultrasound-responsive:  
12% in PBS, 24h 
CCRF-CEM cell lines  In vitro  Wang CH, et 
al. 2012 
DNA (41)  Carbon nanotube  Daunorubi-
cin 
LP 157%  pH-responsive:  
60%, 72h 
Molt-4, U266  In vitro  Taghdisi SM, 
et al. 2011 
DNA (41)  Apt-drug conjugate  Dox  Dox/sgc8c ratio: 1/1 
(molar) 
DNS  CCRF-CEM cell lines  In vitro  Huang YF, et 
al. 2009 
Ploy-Apt 
/PTK7 
DNA(41)n  Apt-drug conjugate  Dox  Apt/drug ratio: 1/10 
(molar) 
Nuclease-responsive  CCRF-CEM cells, Ramos 
cells 
In vitro  Zhang ZQ, et 
al. 2013 
Apt 
/EpCAM 
RNA (14)  PLGA NPs  Curcumin  EE: 89.98%  Hydrolytic release: 
 81% in PBS, 100h 
HT 29, HEK293T  In vitro  Li L, et al. 2014 
EpDT3 
/EpCAM 
RNA (19)  Apt-drug conjugate  Dox  Apt-Dox ratio: 1:2 
(molar) 
Hydrolytic release:  
37% in PBS, 6h 
Y79 and WERI-Rb1  In vitro  Subramanian 
N, et al. 2012 
DDSs  
/Cyt c 
DNA (48)  Silica-shelled gold 
nanorods 
Rotenone  LP 7.3%  Photothermo-responsive: 
25%, 12h 
Hela cells  In vitro  Ju EG, et al. 
2014 
Apt 
/CD30 
RNA (39)  HAuNS  Dox  EE 90%, LP 30%  pH-responsive:  
80% in PBS, 2h 
Karpas 299, SUDHL-1  In vitro  Zhao NX, et al. 
2013 
TLS11a 
/LH86 
DNA (63)  Apt-drug conjugate  Dox  Apt/Dox ratio: 1/25 
(molar) 
DNS  NOD. Cg-Prkdc mice 
bearing xenograft (LH86 
cells) 
In vitro &  
in vivo  
Meng L, et al. 
2012 
HB5 
/HER2 
DNA (86)  Apt-drug conjugate  Dox  Apt-Dox ratio: 1/10 
(molar) 
DNS  SK-BR-3,MDA-MB-231, 
MCF-7 
In vitro  Liu Z, et al. 
2012 
*triblock copolymer: [pPEGMA-PCL-pPEGMA= poly(polyethylene glycol methacrylate)-poly(caprolactone)-poly(polyethylene glycol methacrylate. 
Abbreviation: SPIO, superparamagnetic iron oxide; Ptx, paclitaxel; HAuNS, hollow gold nanosphere; Dox, doxorubicin; Apt, aptamer; QD, Quantum dot;  AuNR, gold 
nanorods; EE, encapsulation efficiency; LP, loading percentage; DNS, data not shown. 
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Figure 2. A schematic illustration of novel forms of advanced AMNVs and their tumoricidal response in vitro and in vivo. (A) Li-
pid-polymer hybrid NPs combining the positive attributes of both liposomes and polymeric NPs and comprising a hydrophobic polymeric core (PLGA, drug 
and fluorescent dye) and a lipid layer conjugated to aptamers. (B) Self-assembled hybrid nanoparticles for the targeted co-delivery of two different drugs to 
cancer cells. A lipid-PEG-aptamer loaded with Dox forms the hydrophilic shell, whereas PLGA encapsulating PTX forms the hydrophobic core. (C) A 
poly-aptamer-drug composition based on rolling-circle amplification that induces cooperative binding and increases the strength and frequency of inter-
actions with target tumor cells. (D) Aptamer-tethered DNA nanotrains, self-assembled from short DNA building blocks upon initiation from a chimeric 
aptamer-tethered trigger probe, significantly improve the drug payload capacity and the anti-tumor efficacy. (E-G) Increased endocytosis, cisplatin-d (GpG) 
intrastrand cross-links and cytotoxicity to tumor cells were confirmed by confocal laser scanning microscopy using different fluorescent probes (NR dye, 
R-C18 antibody and tubulin marker, respectively). Left, non-targeted NPs; right, aptamer-functionalized NPs. (H) The biodistribution discrepancy between 
non-targeted (left) and Muc1-targeted (right) QD-Dox conjugates shows active tumor targeting by preferentially accumulating in subcutaneous ovarian 
tumors. Adapted from [21, 24, 26]. 
 
From this perspective, it is worth noting that an 
innovative delivery form named a “molecular train” 
was recently described by Tan [26]. This form can 
significantly improve the drug loading capacity by as 
much as 10-fold. In brief, a molecular train is an as-
sembly of an aptamer moiety on one end, serving as 
the locomotive, and tandem modules at the other end, 
serving as the boxcars by integrating the drug into 
phosphoramidites based on a solid-phase synthesis 
platform (Fig. 2D). Furthermore, specific linkers can 
be added between the two to enable photothermal- or 
pH-responsive release [27].  
 Notably, as a progressive formulation integrat-
ing natural and artificial nanomaterials at physiolog-
ical conditions, a class of aptamer-based DNA 
nanostructure shows greater promise as candidates 
for targeted drug delivery and cancer therapy with 
the characteristics of multiple functionality and high 
programmability. These novel nanoassemblies, re-
ported as nanoflower, nanorobot, DNA origami, and 
aptamer-micelle self-assemblies [28-31], are capable of 
hybridizing the predesigned DNA building blocks 
from one-dimensional into two-  and  three- 
dimensional nanostructures. By precise program- Theranostics 2014, Vol. 4, Issue 9 
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ming, many myriad functional moieties, such as can-
cer-targeting aptamers, intercalated anticancer drugs, 
therapeutic antisense oligonucleotides, and fluores-
cent bioimaging components, can be readily intro-
duced to construct a single nanoassembly, with the 
advantage of facile assembly, high packaging effi-
ciency, thousand-fold loading of chemotherapeutic 
and bioimaging agents, along with possible solutions 
to chemoresistance [32].  
Progress in AMNVs used in anti-cancer 
nanomedicine  
 A renowned aptamer in anti-cancer research is 
AS1411, a 26-nucleotide guanosine-rich DNA se-
quence discovered by Bates et al. in 1914 [33]. AS1411 
specifically binds to overexpressed or translocated 
nucleolin (NCL) in many types of cancer cells [34]. A 
range of preclinical studies have shown significant 
inhibition of various tumor cell lines at very low con-
centrations, with good efficacy and minimal side ef-
fects (Table 2). For example, one comprehensive study 
reported a formulation of AS1411-functionalized lip-
osomes encapsulating Dox. In vitro results indicated a 
high targeting efficiency and enhanced cytotoxicity in 
MCF-7 cells, and the targeted liposomes also im-
proved anti-tumor efficacy against xenografted 
MCF-7 breast tumors in nude mice due to enhanced 
tumor tissue penetration and the early onset of tumor 
suppression [35]. Except for the chemotherapeutic 
toxicity, the anti-cancer effects of AS1411 included 
two specific mechanisms: blockade of the binding of 
NCL to the Bcl-2 oncogene, which induces the escape 
of cells from apoptosis, thereby enabling tumorigen-
icity, and inhibition of the signaling of the 
pro-survival molecule NF-κB,  which  otherwise 
maintains DNA replication and inhibits cell cycle ar-
rest [36, 37]. 
 This preclinical success inspired great interest in 
the clinical study of AS1411. Based on early-stage data 
from a phase I clinical trial supporting its safety and 
maximum tolerated dose in advanced solid tumors, 
the tumoricidal effect of its commercial version (gen-
erated by Aptamera Inc., Louisville, KY) is being in-
vestigated in phase II trials for acute myeloid leuke-
mia (AML) and renal cell carcinoma (RC) [38]. An 
early phase II trial for AML demonstrated that com-
bination with cytarabine was superior to cytarabine 
alone [39]. However, a recently published report in-
cluding 36 cases of RC unveiled minimal responses to 
AS1411 (<3%) in unselected cases, except in one case 
with FGFR2 and mTOR mutations [40].  
 Compared with the diverse and even contra-
dictory results for AS1411, another valuable discovery 
was aptamer A10, whose use has been focused on 
prostate cancer research for decades. A10 is an ap-
tamer that binds to a hallmark antigen on prostate 
cancer cell surfaces, named prostate-specific mem-
brane antigen (PSMA), which is predominantly ex-
pressed on the vasculature of many neoplasms but 
that shows very low expression in normal tissue [41]. 
Many studies have revealed encouraging results for 
the advancement of anti-prostate cancer nanomedi-
cine using A10. 
 In one preliminary study, A10 was conjugated 
to PLGA NPs for the controlled release of a platinum 
compound (PtIV), which was reduced to cisplatin (Pt) 
intracellularly. A  lethal dose of Pt was specifically 
delivered to LNCaP cells, with evidence of endocyto-
sis and nuclear DNA cross-links (Fig. 2E and F). The 
A10-NPs were 80 times more toxic than free Pt was, 
and the IC50 was only a quarter of that of 
non-targeted NPs [19].  
 To further improve the drug encapsulation effi-
ciency and co-delivery of multiple drugs for com-
bined chemotherapy, another study constructed an 
A10-functionalized, dual-drug delivery NP platform 
with high loading of hydrophilic PtIV and hydro-
phobic Dtxl. This powerful carrier exhibited 10-fold 
increased toxic efficacy compared with a single PtIV 
carrier (Fig. 2G) [42]. The significance of this study lies 
in the strategy used to minimize the batch-to-batch 
variability of the NPs during synthesis and the poten-
tial for combination therapy. Interestingly, the ap-
tamer density on the NP surface can be precisely 
tuned by adjusting the mixing ratio of the 
PLGA-PEG-A10 tri-block copolymer with the 
PLGA-PEG di-block copolymer. The optimum ligand 
density for PSMA-specific endocytosis was estimated 
to range from 10-80 nmol of aptamer per μmol of NPs. 
This minimum amount was considered to be an op-
timal ligand density that conferred the maximal tar-
geted cellular uptake. This theory was confirmed by 
comparative NP biodistribution studies in vivo using 
an LNCaP xenograft mouse model [43].  
 In addition to enhanced tumor cytotoxicity, 
certain non-polymer-based NPs offer enhanced 
choices for monitoring the real-time behaviors of 
AMNVs by visualizing drug transportation to tumor 
sites. For example, a QD-mucin 1 aptamer-Dox con-
jugate exhibited preferential accumulation in ovarian 
carcinoma resulting from implantation of a subcuta-
neous tumor for in vivo targeting (Fig. 2H). Moreover, 
A9 (a predecessor of A10) and A10 PMSA aptamers 
were each conjugated to GNPs and superparamag-
netic iron oxide (SPIO) NPs, both of which can be 
tracked when they specifically bind to prostate cancer 
using clinical CT and MRI [44,45]. This system fulfills 
the dual demands of both fluorescent/radiographic 
contrast and a drug delivery system. 
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aptamers is that they fully embody the extension of 
the cancer spectrum for in vivo and in vitro evalua-
tion. These aptamers can also be upgraded as refined 
aptamers, such as the updating of PMSA aptamers 
from the previous A9 to the current A10.3. In fact, 
following insight into novel tumor biomarkers, other 
new aptamers are still currently under selection and 
investigation. These studies offer a solid 
proof-of-concept for drug delivery strategies and tu-
mor-targeting approaches. For example, an ap-
tamer-equipped hollow GNP carrying Dox was fab-
ricated to target CD30 (a cell membrane protein of the 
tumor necrosis factor receptor family) on lymphoma 
cells [46]. In another study, a PLGA-lecithin-PEG NP 
targeting endothelial cell adhesion molecule (Ep-
CAM) was prepared to selectively deliver curcumin to 
colon cancer cells [47]. In addition, the human epi-
dermal growth factor receptor 2 (HER2) aptamer HB5 
and the mucin 1 aptamer MA3 were developed to 
exploit their tumoricidal effects on breast and lung 
cancers  [48, 49].  Other parallel studies are summa-
rized in Table 2. Of note, a non-polymeric drug 
transport platform called aptamer-tethered DNA na-
notrains (apt-NTrs) was recently presented by Tan et 
al  [26]. In their series of studies, sgc8-NTrs were 
self-assembled from two short hairpin DNA mono-
mers upon initiation from a modified ap-
tamer-tethered trigger probe (Fig. 2D). These na-
notrains selectively transported a drug payload to 
target leukemia cells and offloaded the drug to induce 
tumor cytotoxicity in both in vitro and in vivo models. 
This system presents advances in terms of its simple 
design and preparation, high payload capacity, and 
optional upload of theranostic agents into the tandem 
repetitive cargo. 
Limitations of aptamers in chemotherapy  
Compared with antibody-mediated nanovehi-
cles, aptamers are prone to unbinding from receptors, 
resulting in pharmacokinetic instability and rapid 
systemic clearance. Several discussions about the in-
sufficient affinity of aptamers for their receptors have 
suggested suboptimal bioavailability and anti-cancer 
efficacy. Most reports have proposed that the affinity 
of aptamers, quantified using the value of the disso-
ciation constant (Kd), is generally 30-300 nM [23-26, 
44-49]. However, a study on 840 rabbit monoclonal 
antibodies (http://www.abcam.com/index.html? 
pageconfig=resource&rid=15749) revealed that their 
affinities were nearly 1000 times higher than those of 
aptamers (Kd: 10-1000 pM). This theoretical discrep-
ancy was elucidated by one study aiming to evaluate 
the targeting selectivity, extent of internalization, and 
anti-cancer efficacy of liposomes loaded with the 
α-particle generator 225Ac to kill PSMA-expressing 
tumor cells. The liposomes were labeled with the 
PSMA J591 antibody or with the A10 aptamer [50]. 
The results demonstrated that the J591-labeled lipo-
somes display significantly higher levels of conjunc-
tion intensity, total specific binding and cytotoxicity 
to PMSA (+) cell lines than do A10-labeled liposomes.  
 Another concern is that secondary targets 
would be affected following aptamer treatment be-
cause of these targets’ minimal or unknown mecha-
nism in normal tissues and the multifunctional nature 
of aptamer-targeting receptors. For example, physio-
logically, NCL exerts its principal functions in rRNA 
synthesis, ribosome biogenesis, and cell cycle modu-
lation [51]. Several unpredictable outcomes, such as 
dysregulated gene silencing and cell cycles and even 
the phenotypic transformation of cancer cells, might 
emerge following AS1411 treatment.  
 The third limitation is that few measures can be 
taken when we treat certain cancers with negative 
signatures using AMNVs. Triple-negative breast 
cancer, one pathological type that completely lacks 
the estrogen receptor (ER), the progesterone receptor 
(PR) and HER2, currently has no effective solution 
except for surgery and combined chemotherapy [52]. 
The lack of biomarkers for certain cancers makes them 
more difficult to treat, so most targeted therapies will 
be in vain.  
Current concepts in tumorigenesis and 
implications for aptamer-related chemo-
therapy  
Tumor heterogeneity  
 One issue troubling researchers is that many 
drug delivery vehicles appear particularly promising 
in preclinical studies but fail unexpectedly in clinical 
evaluations. Despite hundreds of preclinical confir-
mations, AS1411 was reported to be ineffective in its 
anti-cancer activity in a phase II clinical trial for RC 
[40]. This finding was a profound enlightenment, 
although this result is still not conclusive. Currently, it 
is recognized that tumor heterogeneity is one of the 
significant reasons underlying this effect, in addition 
to chemoresistance and cancer relapse [53, 54]. In-
creasing evidence continues to show that tumor het-
erogeneity can be manifested in at least three ways: (1) 
tumor entities comprising  heterogeneous cells with 
different phenotypic properties, which may variously 
contribute to the progression of the malignancy; (2) 
pathological diversified tissue formation observable 
within the same tumor, with at least five subtypes 
categorized for breast cancer, based on the varying 
presence of receptors; and (3) tumor cells recovered 
from metastatic sites that may be a newly acquired 
variant compared with the original tumor [55,56].  Theranostics 2014, Vol. 4, Issue 9 
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Heterogeneity presents a great challenge in terms of 
targeting therapeutics because the current tumor 
models for cancer toxicity generally operate on the 
premise of homogeneity, and these models are not 
ideal biomimetic niches to simulate variability. 
Moreover, the majority of current AMNVs only spe-
cifically bind to one type of receptor, and subpopula-
tions of other cells within the tumor will not be af-
fected by the drug mechanism and will easily acquire 
MDR [57].  
 One possible solution is chimerization or mul-
ti-conjugation strategies, referring to combination 
with another aptamer, a biomacromolecule and/or a 
small molecular compound, in which the functional 
capability of the chimera is the superposition of the 
aptamer and these molecules [58]. The aim is to 
broaden the range of recognition of different cell 
subpopulations within a tumor. This goal was sub-
stantiated by several preliminary studies, including a 
study on multi-specific and self-assembled drug ve-
hicles generated based on the monovalent aptamers 
sgc8c and sgd5a. These aptamers are capable of rec-
ognizing and killing different leukemia cell lines, in-
cluding CEM, Ramos, and Toledo cells. Other studies 
have examined an anti-HER2 antibody and S6 RNA 
aptamer-equipped GNPs capable of detecting differ-
ent breast cancer cells and a dual-aptamer SPIO-NP 
system co-conjugated with the A10 and DUP-1 pep-
tide aptamers, which induce selective cell uptake and 
effective drug delivery to both PSMA (+) and PSMA (-) 
cancer cells [59-61] (Fig. 3).   
 
 
 
Figure 3. The role of the tumor niche in the origin and influence of tumor heterogeneity, hypoxic aberrancy and the tumor-stroma 
interactome. Tumorigenesis involves the co-evolution of tumor cells with the ECM and vascular endothelial, immune and stromal cells (adapted from 
[52]). Various anti-tumor strategies can be used to develop advanced AMNVs to overcome current limitations in chemotherapy, such as chimerization, 
co-delivery with siRNA, and stroma-targeted nanomedicine, among others. Aptamer is abbreviated as apt in this figure. * CEM and Toledo are different 
hemopoietic cancer cell lines; **MDA-MB-231 and SK-BR-3 are different breast cancer cell lines. 
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Another possible route is a cancer stem cell 
(CSC)-based strategy. CSCs are tumor cells showing 
self-renewal and multi-lineage differentiation proper-
ties that are believed to be the central echelon of the 
cellular hierarchy present within tumors and to drive 
further heterogeneity [62]. Despite continuing con-
troversy about their existence and their proposed role 
in tumor maintenance, anti-cancer strategies targeting 
CSCs are widely accepted as a path-breaking ap-
proach. To date, dozens of reports have paved the 
way for CSC-targeting therapies, such as those seek-
ing biomarkers of CSCs and targeting genes that reg-
ulate the malignant activities of CSCs. These example 
suggest that aptamers designed to target specific 
hallmarks of CSCs within brain and colon cancers 
(such as CD133), as well as AMNVs carrying cyto-
toxins or siRNAs, should be theoretically possible [63, 
64].  
 Above all, a prerequisite for the tactics discussed 
here is knowledge of the specific pathological and 
immunohistological evidence provided by tumor bi-
opsies. The identification of these important charac-
teristics will permit a better definition of tumor het-
erogeneity, which may ultimately lead to better 
treatment strategies. However, currently, the compli-
cated genetic, epigenetic, phenotypic and morpho-
logic mechanisms underlying heterogeneity present a 
huge challenge for these investigations. 
 Hypoxia-induced aberrant EPR and MDR  
 One of the most validated issues in oncology is 
that most growing, solid tumors contain regions ex-
periencing hypoxia [65]. Hypoxia inhibits standard 
anti-cancer therapies by reducing drug inflow into the 
cell, increasing drug outflow from the cell, enhancing 
anti-cancer-drug metabolism, increasing DNA repair, 
and obstructing programmed cell death [66]. In addi-
tion to tumor heterogeneity and stemness, the cellular 
hypoxia machinery drives most aspects of impaired 
EPR and MDR, which may inspire the improvement 
of AMNVs based on the following mechanisms.  
 First, the poorly formed vasculature and diffu-
sion barrier hamper the transport of the drug-carrying 
nanovehicle into the center of the tumor, thereby im-
pairing EPR and reducing cytotoxicity in hypoxic re-
gions [67, 68]. Because the majority of AMNVs are 
administered systemically, such as by intravenous 
injections, they reach the tumor site via the systemic 
circulation. The drug administration route can be op-
timized by localized delivery and regional release 
using a controllable vehicle, such as in situ-forming 
gels [69]. It would be beneficial to reduce systemic 
distribution and to increase the intratumoral concen-
tration by using a strong aptamer-receptor binding 
moiety. Chemotherapeutic killing could also be in-
creased by targeted injection into the central hypoxic 
area of the tumor mass with ultrasonic or radio-
graphic assistance; by locoregional regimens, such as 
aerosols for pulmonary cancer; or by transcatheter 
arterial administration for hepatocellular carcinoma. 
 Second, cancer cells can maintain a high glyco-
lytic rate, even under oxygen-saturated conditions 
[70]. This metabolic shift, defined as the Warburg ef-
fect, is considered to be a major contributor to 
chemoresistance [71]. It is known that the process is 
controlled by two key regulators: hypoxia-inducible 
factors 1 and 2 (HIF-1, 2), which primarily modulate 
tumor glycolysis and lipid metabolism and further 
affect the processes of angiogenesis and vasculariza-
tion [72, 73]. Thus, AMNVs carrying a hypoxic cyto-
toxin/antagonist or a specific inhibitor targeted 
against HIF-1 and HIF-2 and their target genes, such 
as pyruvate dehydrogenase kinase (PDK) [74], may be 
beneficial for reversing the intracellular hypoxic me-
tabolism and increasing the effectiveness of hypox-
ia-targeted therapies (Fig. 3). In particular, a series of 
studies has suggested that it is possible to reduce 
metabolic flexibility and to reverse the Warburg effect 
in cancer cells to improve chemotherapeutic sensitiv-
ity by inhibiting HIF using NSC-134754, cetuximab, 
tirapazamine and echinomycin, among others [75-77]. 
Third, it has been illustrated that hypoxia also 
upregulates the expression of certain ATP-binding 
cassette genes (ABCB1, 2); increases the activity of 
efflux transporters, such as P-glycoprotein (P-gp), a 
protein encoded by multidrug resistance protein 1 
(MRP1); and finally leads to an ATP-dependent de-
crease in cellular drug accumulation, resulting in 
treatment failure [78]. Recent studies in nanomedicine 
have presented several inspired approaches to over-
come MDR by inhibiting the translation of the 
mRNAs of MDR efflux pump proteins, such as MDR1 
or MRP1, by using siRNA or antisense oligonucleo-
tides [32, 79, 80], or by blocking MDR efflux proteins, 
such as P-gp/ABCB1 or MRP1/ABCC1, using 
chemosensitizers (e.g., verapamil) or small-molecule 
compounds and/or antibodies [81-83]. Therefore, 
silencing these target genes using integrated AMNVs 
that deliver a construct of single or multiple siRNAs 
or a pharmacologic antagonist that improves the sen-
sitivity of chemotherapy is plausible (Fig. 3). This 
strategy was verified in a preliminary attempt that 
used a dual minicell system in which sequential de-
livery of si/shRNA-encoding plasmids was used to 
knock down MDR1/P-gp and cytotoxic drugs were 
used to eliminate tumor xenografts [84]. Additionally, 
a recent advanced study used azobenzene as a hy-
poxia-responsive bioreductive linker for the hypox-
ia-targeted delivery of siRNA to downregulate 
GFP-expressing tumors [85].   Theranostics 2014, Vol. 4, Issue 9 
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Tumor-stroma interactome in 
microenvironment 
 It is apparent that the genetic and phenotypic 
properties of cancer cells alone are not enough to en-
able cancer progression without a supporting micro-
environment [86]. In fact, cancer cells and their stro-
mal partners coordinate in many processes that con-
trol tumorigenesis. This bidirectional crosstalk was 
fully replicated in a prostate cancer model that pro-
vided evidence that the progression from original 
growth to distant bone metastasis was further pro-
pelled by the cancer-associated stroma (CAS) [87]. In 
particular, permanent genetic or phenotypic changes 
were noted in cancer cells when they were co-cultured 
with CAS cells, such as fibroblasts and macrophages 
[88]. Moreover, cancer-associated fibroblasts enhance 
the secretion of SDF-1, TGF-β1, interleukin-6 (IL-6), 
and matrix metalloproteinase 9 (MMP-9) to facilitate 
the detachment and invasion of cancer cells [89, 90]. 
Additionally, hypoxia recruits macrophages that pro-
vide trophic function to stimulate angiogenesis by 
expressing VEGF and angiopoietin, these cells also 
produce epidermal growth factor (EGF), tumor ne-
crosis factor (TNF), TGF- β and IL-8, contributing to 
matrix breakdown and tumor cell motility and 
providing proliferative and anti-apoptotic support[91, 
92]. These findings suggest that the previously un-
derestimated CAS is an important therapeutic target 
for AMNVs. Along these lines, a specific aptamer that 
uses IGFBP7 or CD163 could be designed to enhance 
tumor ablation by identifying the tumor stromal 
markers of  epithelial cancers and mesen-
chyme-derived sarcomas [93, 94] (Fig. 3). 
 Additionally, the inclination of prostate cancer 
to metastasize into bone tissue encouraged research-
ers to unveil the participation of extracellular matrix 
(ECM) components in cancer progression. In one 
study,  integrin  α2β1-overexpressing LNCaP prostate 
cancer cells derived from successive plating on type I 
collagen (COL-I) displayed enhanced chemotactic 
migration toward COL-I, the most abundant bone 
protein[95], by inhibiting the activation of the sup-
pressor gene BRCA2, thereby reducing E-cadherin 
expression and upregulating the PI3K/Akt pathway 
[96,97]. It is highly plausible that the ECM plays a 
pivotal role in the epithelial-mesenchymal transition 
(EMT). Thus, whole-cell-recognizing AMNVs binding 
to COL-I-secreting cells, such as cancer-associated 
fibroblasts, and aptamers targeting integrin 
α2β1-overexpressing cancer cells may be a therapeutic 
alternative for intervening in the progression of the 
EMT. 
Conclusions and Perspectives 
 An imminent human disaster was forecasted by 
the WHO, based on the prediction that cancer cases 
are expected to surge by 57% in the coming 20 years 
and to exceed 13.1 million [69]. Therefore, advanced 
weaponry will definitely be required to conquer can-
cer. However, current chemotherapy lacks specificity, 
so the majority of chemotherapeutics agents induce 
deleterious side effects and genetic and phenotypic 
transformations resulting in tumor chemoresistance 
and regression. The emergence of aptamers imbues 
nanoscale vehicles with the property of specificity to 
minimize “off-target” effects, and a variety of tumor-
icidal agents (e.g., chemotherapy drugs, cytotoxins, 
and siRNAs) have been directionally delivered to 
cancer cell lines associated with nearly all clinical 
cancers using the modalities of NPs, QDs, liposomes, 
hydrogels and other self-assembled constructs [35, 42, 
44, 45, 98, 99]. Although these AMNVs have displayed 
advantageous enhanced selective killing via EPR ef-
fects to suppress malignant progression, to our 
knowledge, numerous limitations should be ad-
dressed prior to entering clinical trials with these 
nanovehicles and permitting their use in the daily 
management of cancer. 
 The requirement to optimize the intrinsic pa-
rameters of aptamer-nanovehicle entities continues, 
and the detailed internalization mechanisms of AM-
NVs are still elusive. After endocytosis by a cancer 
cell, AMNVs undergo very complicated cytoplasmic 
processes, such as protein binding, transporter deliv-
ery, oxidation and ubiquitylation, and infiltration 
through multiple barriers or compartments [7, 
100-102]. Further understanding of the intracellular 
interactions will significantly improve the flexibility 
and bioavailability of nanovehicles in tumors, such as 
by enhancing their accumulation and extravasation, 
thereby damaging the tumor vasculature [103, 104].  
 The spectrum of recognition targets should also 
be significantly extended. Previous aptamers have 
been primarily used to target transmembrane pro-
teins, but their use in modulating the function of in-
tracellular proteins has been limited due to a poor 
understanding of the mechanisms. In the coming 
years, many proteins/antigens contributing to the 
progression of tumors, either in the cytoplasm or in 
the nucleus, may be worthy of therapeutic targeting 
instead, using specially designed aptamers. Further-
more, using this strategy, many of the cancer-related 
transcriptional factors and oncogenes, such as the 
transcription factor NF-κB  and its responsive genes 
Bcl-xl, HIF-1α and VEGF [105-107], which are critical 
for the establishment of malignancies, could possibly 
be modulated by aptamers. This theory is supported 
by a study that blocked the activation of NF-κB and 
reversed Dox-induced chemoresistance using a novel 
adenoviral expression system to deliver an RNA ap- Theranostics 2014, Vol. 4, Issue 9 
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tamer directly targeted to the p50 subunit of NF-κB 
[108]. 
 Another approach is the use of genetic and epi-
genetic modulations based on whole-genome se-
quences at the single-cell level and on tumor au-
to-biopsies [53]. Various miRNAs have been shown to 
possess tumor-suppressing potency in breast, colon, 
and hematological malignancies, among others [109]. 
Therefore, these miRNAs can be targeted to cancer 
cell signaling components or EMT regulators, and 
aptamers can be utilized to direct the application of 
miRNAs to the malignant machinery [110]. It is an-
ticipated that the interdisciplinary combination of 
aptamer chemistry, chemo-pharmaceutics and RNA 
interference-based techniques will potentiate the ma-
nipulation of key molecular events associated with 
cancer initiation and progression at both the tran-
scriptional and the posttranscriptional levels [111].  
 With expanding knowledge of the genome, 
epigenome, transcriptome, proteome and metabo-
lome [112], another prospective avenue will be per-
sonalized oncology. Instead of the traditional “one 
treatment fits all” paradigm, more attention will be 
paid to determining the genetic, epigenetic, pheno-
typic, and morphologic characteristics of a tumor in 
individual samples using whole-genome sequences, 
mass spectroscopy-based proteomic analyses, and 
next-generation sequencing [113] to uncover specific 
tumor biomarkers/antigens, oncogenes, and 
non-coding regulators, with very high resolution. 
Based on these personalized data, an ideal profile of 
an advanced AMNV may be sketched to generate a 
selective and integrative nanoplatform that incorpo-
rates multiple or chimeric aptamers for targeting, 
tumoricidal chemotherapeutics/cytotoxins, RNA in-
terference that blocks the mechanisms of oncogene 
activation and chemoresistance, an epigenetic regu-
lator targeting tumor progression, and a biocompati-
ble nanocarrier [114].  
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